Clinical Trial to Evaluate Safety, Tolerability and Efficacy of NFX88 in SCI
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 60
Summary
- Conditions
- Neuropathic Pain
- Spinal Cord Injuries
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 80 years
- Gender
- Both males and females
Description
This is a Phase IIa (proof of concept), randomized, double-blind, placebo controlled, parallel group, multicentric, clinical trial to evaluate the safety, tolerability and efficacy of daily oral treatment with NFX88 in SCI patients who are not receiving opiates or cannabinoids and present neuropathi...
This is a Phase IIa (proof of concept), randomized, double-blind, placebo controlled, parallel group, multicentric, clinical trial to evaluate the safety, tolerability and efficacy of daily oral treatment with NFX88 in SCI patients who are not receiving opiates or cannabinoids and present neuropathic pain with an average pain score ? 4 measured with a VAS scale during the last week at screening
Tracking Information
- NCT #
- NCT04148573
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: ANTONIO OLIVIERO, MD HOSPITAL DE PARAPLEGICOS DE TOLEDO
Get Well Soon